{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T16:21:21Z","timestamp":1774282881674,"version":"3.50.1"},"update-to":[{"DOI":"10.1002\/14651858.cd001506.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T00:00:00Z","timestamp":1686700800000}}],"reference-count":180,"publisher":"Wiley","issue":"6","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd001506.pub5","type":"journal-article","created":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T11:44:51Z","timestamp":1686743091000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Nebulised hypertonic saline for cystic fibrosis"],"prefix":"10.1002","volume":"2023","author":[{"given":"Peter","family":"Wark","sequence":"additional","affiliation":[{"name":"Centre for Healthy Lungs; Hunter Medical Research Institute, University of Newcastle; New Lambton Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa M","family":"McDonald","sequence":"additional","affiliation":[{"name":"Centre of Excellence in Severe Asthma and Priority Research Centre for Healthy Lungs; The University of Newcastle; Newcastle Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherie","family":"Smith","sequence":"additional","affiliation":[{"name":"Division of Child Health, Obstetrics & Gynaecology (COG), School of Medicine; University of Nottingham; Nottingham UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,6,14]]},"reference":[{"issue":"Suppl 1","key":"10.1002\/14651858.CD001506.pub5-BIB0001|cit1","first-page":"S66","article-title":"Hypertonic saline X recombinant human DNase: a randomised crossover study in 18 cystic fibrosis patients","volume":"3","author":"Adde","year":"2004","journal-title":"Journal of Cystic Fibrosis"},{"issue":"5","key":"10.1002\/14651858.CD001506.pub5-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1136\/thx.2009.125831","article-title":"Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function","volume":"65","author":"Amin","year":"2010","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0003|cit3","first-page":"289, Abstract n","article-title":"Inhaled hypertonic saline (7%) improves LCI in paediatric CF patients with normal lung function [abstract]","volume":"44 Suppl 32","author":"Amin","year":"2009","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0004|cit4","unstructured":"The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis clinicaltrials.gov\/ct2\/show\/NCT00635141"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.rmed.2016.01.020","article-title":"A randomized controlled trial to evaluate the lung clearance index as an outcome measure for early phase studies in patients with cystic fibrosis","volume":"112","author":"Amin","year":"2016","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0006|cit6","unstructured":"A randomized-controlled trial of inhaled hypertonic saline (7%) to evaluate the lung clearance index clinicaltrials.gov\/ct2\/show\/NCT02276898"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0007|cit7","unstructured":"Ballmann M von der Hardt H Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis [abstract] Proceedings of the 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin 1998 80"},{"issue":"1","key":"10.1002\/14651858.CD001506.pub5-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1569-1993(01)00009-1","article-title":"Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis","volume":"1","author":"Ballmann","year":"2002","journal-title":"Journal of Cystic Fibrosis"},{"issue":"Suppl 45","key":"10.1002\/14651858.CD001506.pub5-BIB0009|cit9","first-page":"231s","article-title":"Effects of exhaled nitric oxide levels and lung function of ultrasonically nebulized hypertonic saline solution in cystic fibrosis","volume":"22","author":"Cardinale","year":"2003","journal-title":"European Respiratory Journal"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD001506.pub5-BIB0010|cit10","first-page":"A43","article-title":"Effect of hypertonic saline, isotonic saline and water challenges on the airways of cystic fibrosis patients","volume":"52","author":"Chadwick","year":"1997","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"eS356","DOI":"10.1016\/j.physio.2015.03.568","article-title":"A randomised controlled trial of hypertonic saline inhalation to enhance airway clearance physiotherapy in adults hospitalised with Cystic Fibrosis (CF)","volume":"101","author":"Dentice","year":"2015","journal-title":"Physiotherapy\u00a0"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0012|cit12","first-page":"257","article-title":"A randomised trial of hypertonic saline nebulisation during hospitalisation for pulmonary exacerbation in adults with cystic fibrosis","volume":"47 Suppl","author":"Dentice","year":"2012","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/S1569-1993(13)60117-4","article-title":"A randomised controlled trial of the effect of hypertonic saline (HS) inhalation on exacerbation resolution, hospital length of stay and time to relapse in adults with cystic fibrosis","volume":"12 Suppl 1","author":"Dentice","year":"2013","journal-title":"Journal of Cystic Fibrosis"},{"issue":"2","key":"10.1002\/14651858.CD001506.pub5-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/thoraxjnl-2014-206716","article-title":"A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis","volume":"71","author":"Dentice","year":"2016","journal-title":"Thorax"},{"issue":"6","key":"10.1002\/14651858.CD001506.pub5-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.jcf.2020.07.009","article-title":"A four week trial of hypertonic saline in children with mild cystic fibrosis lung disease: effect on mucociliary clearance and clinical outcomes","volume":"19","author":"Donaldson","year":"2020","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0016|cit16","first-page":"280","article-title":"Sustained effect of hypertonic saline on mucociliary clearance in CF children with mild lung disease","volume":"48 Suppl 36","author":"Donaldson","year":"2013","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0017|cit17","first-page":"354","article-title":"A four-week trial of hypertonic saline for children with mild cf lung disease: effect on mucociliary clearance, lung function and symptoms","volume":"54 Suppl 2","author":"Donaldson","year":"2019","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0018|cit18","unstructured":"Effect of hypertonic saline on mucus clearance in children ages 5-12 with cystic fibrosis clinicaltrials.gov\/ct2\/show\/study\/NCT01031706"},{"issue":"Suppl 27","key":"10.1002\/14651858.CD001506.pub5-BIB0019|cit19","first-page":"329","article-title":"Long-term inhalation of hypertonic saline in patients with cystic fibrosis - a randomised controlled trial","volume":"38","author":"Bye","year":"2004","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1016\/S1569-1993(06)80426-1","article-title":"Three methods of monitoring adherence in a long-term trial in cystic fibrosis","volume":"5 Suppl","author":"Elkins","year":"2006","journal-title":"Journal of Cystic Fibrosis"},{"issue":"Suppl 28","key":"10.1002\/14651858.CD001506.pub5-BIB0021|cit21","first-page":"268","article-title":"Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]","volume":"40","author":"Elkins","year":"2005","journal-title":"Pediatric Pulmonology"},{"issue":"3","key":"10.1002\/14651858.CD001506.pub5-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa043900","article-title":"A controlled trial of long-term hypertonic saline in patients with cystic fibrosis","volume":"354","author":"Elkins","year":"2006","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0023|cit23","unstructured":"The effects of long term inhalation of hypertonic saline in subjects with cystic fibrosis clinicaltrials.gov\/ct2\/show\/NCT00271310"},{"issue":"1","key":"10.1002\/14651858.CD001506.pub5-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jpeds.2006.04.030","article-title":"Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis","volume":"149","author":"Ratjen","year":"2006","journal-title":"Journal of Pediatrics"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0025|cit25","first-page":"306","article-title":"Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience","volume":"Suppl 13","author":"Button","year":"1996","journal-title":"Pediatric Pulmonology"},{"issue":"Suppl 19","key":"10.1002\/14651858.CD001506.pub5-BIB0026|cit26","first-page":"510s","article-title":"Efficacy of short-term ultrasonically nebulised hypertonic saline in patients with cystic fibrosis","volume":"8","author":"Eng","year":"1995","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0027|cit27","first-page":"440","article-title":"Short-term administration of ultrasonically nebulised hypertonic saline improves pulmonary function in patients with cystic fibrosis","volume":"25","author":"Eng","year":"1995","journal-title":"Australian & New Zealand Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD001506.pub5-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/(SICI)1099-0496(199602)21:2<77::AID-PPUL3>3.0.CO;2-M","article-title":"Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis","volume":"21","author":"Eng","year":"1996","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0029|cit29","unstructured":"A clinical trial to compare the effects of 3% and 7% hypertonic saline on lung function in children with cystic fibrosis trialsearch.who.int\/Trial2.aspx?TrialID=CTRI\/2010\/091\/001279"},{"issue":"5","key":"10.1002\/14651858.CD001506.pub5-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1093\/tropej\/fms004","article-title":"Comparison of effects of 3 and 7% hypertonic saline nebulization on lung function in children with cystic fibrosis: a double-blind randomized, controlled trial","volume":"58","author":"Gupta","year":"2012","journal-title":"Journal of Tropical Pediatrics"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1471-2466-11-45","article-title":"Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis","volume":"11","author":"Laube","year":"2011","journal-title":"BMC Pulmonary Medicine"},{"issue":"Suppl 32","key":"10.1002\/14651858.CD001506.pub5-BIB0032|cit32","first-page":"Abstract 77","article-title":"Effects of hypertonic saline on mucocilliary clearance in children with cystic fibrosis\u00a0","volume":"44","author":"Laube","year":"2009","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0033|cit33","unstructured":"Hypertonic saline and mucociliary clearance in children clinicaltrials.gov\/ct2\/show\/NCT01293084"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1016\/S1569-1993(15)30323-4","article-title":"Sinonasal inhalation of isotonic vs. hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - results of a multicentre, double-blind, controlled prospective trial","volume":"14 Suppl 1","author":"Mainz","year":"2015","journal-title":"Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society"},{"issue":"6","key":"10.1002\/14651858.CD001506.pub5-BIB0035|cit35","doi-asserted-by":"publisher","first-page":"e57","DOI":"10.1016\/j.jcf.2016.05.003","article-title":"Sino nasal inhalation of isotonic versus hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - Results of a multicenter, prospective, randomized, double-blind, controlled trial","volume":"15(6)","author":"Mainz","year":"2016","journal-title":"Journal of Cystic Fibrosis\u00a0"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0036|cit36","unstructured":"Sino-nasal inhalation of sodium chloride 6,0% in patients with cystic fibrosis and chronic rhinosinusitis clinicaltrials.gov\/show\/nct01086839"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0037|cit37","unstructured":"Inhaled xylitol versus saline in stable subjects with cystic fibrosis clinicaltrials.gov\/ct2\/show\/NCT01355796"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0038|cit38","unstructured":"Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS) clinicaltrials.gov\/ct2\/show\/NCT01619657"},{"issue":"2","key":"10.1002\/14651858.CD001506.pub5-BIB0039|cit39","first-page":"60","article-title":"Randomized double blind controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS)","volume":"44","author":"Stahl","year":"2018","journal-title":"Atemwegs- und Lungenkrankheiten. Conference: 40th Annual Joint Meeting of the Society for Pediatric Pneumology. Austria"},{"issue":"Suppl 47","key":"10.1002\/14651858.CD001506.pub5-BIB0040|cit40","first-page":"302","article-title":"Randomized, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (presis)","volume":"52","author":"Stahl","year":"2017","journal-title":"Pediatric Pulmonology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD001506.pub5-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/S1569-1993(18)30198-X","article-title":"Randomised, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS)","volume":"17","author":"Stahl","year":"2018","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0042|cit42","first-page":"363","article-title":"Follow-up on PRESIS: long-term-efficacy of preventive inhalation therapy with hypertonic saline in infants with CF","volume":"54 Suppl 2","author":"Stahl","year":"2019","journal-title":"Pediatric Pulmonology"},{"issue":"10","key":"10.1002\/14651858.CD001506.pub5-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1164\/rccm.201807-1203OC","article-title":"Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). A randomized, double-blind, controlled study","volume":"199","author":"Stahl","year":"2019","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0044|cit44","first-page":"306","article-title":"Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience","volume":"Suppl 13","author":"Button","year":"1996","journal-title":"Pediatric Pulmonology"},{"issue":"Suppl 18","key":"10.1002\/14651858.CD001506.pub5-BIB0045|cit45","first-page":"430s","article-title":"A pilot study of inhaled hypertonic saline to increase sputum production in adolescents with cystic fibrosis","volume":"7","author":"Riedler","year":"1994","journal-title":"European Respiratory Journal"},{"issue":"1","key":"10.1002\/14651858.CD001506.pub5-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1440-1754.1996.tb01541.x","article-title":"Inhaled hypertonic saline increases sputum expectoration in cystic fibrosis","volume":"32","author":"Riedler","year":"1996","journal-title":"Journal of Paediatric Child Health"},{"issue":"5","key":"10.1002\/14651858.CD001506.pub5-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1164\/ajrccm.153.5.8630593","article-title":"Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis","volume":"153","author":"Robinson","year":"1996","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"10","key":"10.1002\/14651858.CD001506.pub5-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1136\/thx.52.10.900","article-title":"Effect of increasing doses of hypertonic saline on mucociliary clearance inpatients with cystic fibrosis","volume":"52","author":"Robinson","year":"1997","journal-title":"Thorax"},{"issue":"Suppl","key":"10.1002\/14651858.CD001506.pub5-BIB0049|cit49","first-page":"A70","article-title":"Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis","volume":"153","author":"Robinson","year":"1996","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0050|cit50","first-page":"258","article-title":"Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis","volume":"27","author":"Robinson","year":"1997","journal-title":"Australian and New Zealand Journal of Medicine"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0051|cit51","first-page":"280","article-title":"Effect of inhaling a dry powder of mannitol on mucociliary clearance in adults with cystic fibrosis [abstract]","volume":"Suppl 17","author":"Robinson","year":"1998","journal-title":"Pediatric Pulmonolgy"},{"issue":"3","key":"10.1002\/14651858.CD001506.pub5-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1034\/j.1399-3003.1999.14c30.x","article-title":"The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study","volume":"14","author":"Robinson","year":"1999","journal-title":"European Respiratory Journal"},{"issue":"6","key":"10.1002\/14651858.CD001506.pub5-BIB0053|cit53","first-page":"484","article-title":"The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study [abstract]","volume":"29","author":"Robinson","year":"2000","journal-title":"Pediatric Pulmonology"},{"issue":"3","key":"10.1002\/14651858.CD001506.pub5-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jcf.2014.11.002","article-title":"Initial evaluation of the Parent Cystic Fibrosis Questionnaire--Revised (CFQ-R) in infants and young children","volume":"14","author":"Alpern","year":"2015","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/ppul.23056","article-title":"Pulmonary exacerbations and parent-reported outcomes in children <6 years with cystic fibrosis","volume":"50","author":"Brumback","year":"2015","journal-title":"Pediatric Pulmonology"},{"issue":"3","key":"10.1002\/14651858.CD001506.pub5-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jcf.2015.10.007","article-title":"Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis","volume":"15","author":"Davis","year":"2016","journal-title":"Journal of Cystic Fibrosis"},{"issue":"S35","key":"10.1002\/14651858.CD001506.pub5-BIB0057|cit57","first-page":"302","article-title":"Infant PFTs as an endpoint in the infant study of inhaled saline randomized controlled trial","volume":"47","author":"Davis","year":"2012","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0058|cit58","unstructured":"Hypertonic saline and mucociliary clearance in children clinicaltrials.gov\/ct2\/show\/NCT01293084"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1016\/S1569-1993(12)60157-X","article-title":"Efficacy of hypertonic saline in infants and young children: the ISIS study","volume":"11 (Suppl 1)","author":"Ratjen","year":"2012","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0060|cit60","first-page":"Abstract no: 12","article-title":"Alternative multiple breath washout outcomes for clinical trials in cystic fibrosis","volume":"40 Suppl","author":"Ratjen","year":"2012","journal-title":"European Respiratory Journal"},{"issue":"21","key":"10.1002\/14651858.CD001506.pub5-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1001\/jama.2012.5214","article-title":"Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial","volume":"307","author":"Rosenfeld","year":"2012","journal-title":"JAMA"},{"issue":"21","key":"10.1002\/14651858.CD001506.pub5-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1001\/jama.2012.5214","article-title":"Online supplement to \"Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial\" [online]","volume":"307","author":"Rosenfeld","year":"2012","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0063|cit63","first-page":"172","article-title":"Hypertonic saline in children with CF <6 years of age: Results of the ISIS trial","volume":"47","author":"Rosenfeld","year":"2012","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0064|cit64","first-page":"157, Summary: S","article-title":"Hypertonic saline should be the first drug used in CF [summary]","volume":"48 Suppl 36","author":"Rosenfeld","year":"2013","journal-title":"Pediatric Pulmonology"},{"issue":"4","key":"10.1002\/14651858.CD001506.pub5-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1164\/rccm.201302-0219OC","article-title":"Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline","volume":"188","author":"Subbarao","year":"2013","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"S35","key":"10.1002\/14651858.CD001506.pub5-BIB0066|cit66","first-page":"301","article-title":"Effect of hypertonic saline on lung clearance index in infants and preschool children with CF: a pilot study","volume":"47","author":"Subbararo","year":"2012","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0067|cit67","unstructured":"Saline hypertonic in preschoolers (SHIP) clinicaltrials.gov\/ct2\/show\/NCT02378467"},{"issue":"9","key":"10.1002\/14651858.CD001506.pub5-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/S2213-2600(19)30187-0","article-title":"Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"7","author":"Ratjen","year":"2019","journal-title":"Lancet Respiratory Medicine"},{"issue":"S2","key":"10.1002\/14651858.CD001506.pub5-BIB0069|cit69","first-page":"323","article-title":"Multicenter randomized, controlled clinical trial of inhaled hypertonic saline in preschool children with CF: the Ship study","volume":"53","author":"Rosenfeld","year":"2018","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0070|cit70","unstructured":"Aerosolized hypertonic xylitol versus hypertonic saline in cystic fibrosis (CF) subjects clinicaltrials.gov\/ct2\/show\/NCT00928135"},{"issue":"1","key":"10.1002\/14651858.CD001506.pub5-BIB0071|cit71","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jcf.2019.06.016","article-title":"Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with pulmonary exacerbation of cystic fibrosis","volume":"19","author":"Singh","year":"2020","journal-title":"Journal of Cystic Fibrosis"},{"issue":"1","key":"10.1002\/14651858.CD001506.pub5-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1017\/S0266462303000072","article-title":"A cost-effectiveness analysis of rhDNase in children with cystic fibrosis","volume":"19","author":"Grieve","year":"2003","journal-title":"International Journal of Technology Assessment in Health Care"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD001506.pub5-BIB0073|cit73","first-page":"iii84","article-title":"Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis","volume":"56","author":"Suri","year":"2001","journal-title":"Thorax"},{"issue":"10","key":"10.1002\/14651858.CD001506.pub5-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1136\/thorax.57.10.841","article-title":"Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis","volume":"57","author":"Suri","year":"2002","journal-title":"Thorax"},{"issue":"3","key":"10.1002\/14651858.CD001506.pub5-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1164\/rccm.2110015","article-title":"Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis","volume":"166","author":"Suri","year":"2002","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0076|cit76","first-page":"A75","article-title":"A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis","volume":"55","author":"Suri","year":"2000","journal-title":"Thorax"},{"issue":"9290","key":"10.1002\/14651858.CD001506.pub5-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/S0140-6736(01)06412-1","article-title":"Comparison of hypertonic saline and alternate day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomised trial","volume":"358","author":"Suri","year":"2001","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD001506.pub5-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.rmed.2006.05.012","article-title":"Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial","volume":"101","author":"Suri","year":"2007","journal-title":"Respiratory Medicine"},{"issue":"4","key":"10.1002\/14651858.CD001506.pub5-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/ppul.10442","article-title":"Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis children with cystic fibrosis","volume":"37","author":"Suri","year":"2004","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0080|cit80","doi-asserted-by":"crossref","unstructured":"Suri R Wallis C Bush A Thompson S Normand C Flather M A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis Health Technology Assessment 2002 6 34 iii, 1 60","DOI":"10.3310\/hta6340"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0081|cit81","first-page":"125","article-title":"In vivo use of hypertonic saline in cystic fibrosis","volume":"Suppl 20","author":"Suri","year":"2000","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0082|cit82","first-page":"281","article-title":"Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]","volume":"Suppl 22","author":"Suri","year":"2001","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0083|cit83","unstructured":"Weller P Ingram D Preece M Matthew D A controlled trial of intermittent aerosol therapy in patients with cystic fibrosis [abstract] Proceedings of the 9th Meeting European Working Group for Cystic Fibrosis; 1979 June 12-13; Noordwijkerhout, The Netherlands 1979 58"},{"issue":"1","key":"10.1002\/14651858.CD001506.pub5-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/thx.35.1.42","article-title":"Controlled trial of intermittent aerosol therapy with sodium 2-mercaptoethane sulphonate in cystic fibrosis","volume":"35","author":"Weller","year":"1980","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0085|cit85","unstructured":"Effect of the MetaNeb\u00ae on measures of lung clearance index, other measures of lung function and patient reported outcomes in individuals admitted to hospital for an acute exacerbation of their Cystic Fibrosis: a randomised controlled trial anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?ACTRN=12619001681145"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0086|cit86","unstructured":"Immediate effects of the MetaNeb\u00ae on regional lung perfusion, ventilation and other measures of lung function compared to those of huff and cough in adults with stable cystic fibrosis trialsearch.who.int\/Trial2.aspx?TrialID=ACTRN12621000855820"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0087|cit87","unstructured":"Aquino ES Goto DM Santos AS Coelho CC Fuccio MB Saldiva PHN Effects of hypertonic saline solution and continuous positive airway pressure on respiratory mucus contact angle and mucus transportability by cough in cystic fibrosis patients American Thoracic Society International Conference; 2008 May 16-21; Toronto 2008 Poster #G7"},{"issue":"11","key":"10.1002\/14651858.CD001506.pub5-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.4187\/respcare.01705","article-title":"CPAP has no effect on clearance, sputum properties, or expectorated volume in cystic fibrosis","volume":"57","author":"Aquino","year":"2012","journal-title":"Respiratory Care"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"S104","DOI":"10.1016\/S1569-1993(13)60358-6","article-title":"Randomized double-blind monocentric trial on tolerability, acceptability and efficacy of two formulations of inhaled 7% hypertonic saline with and without hyaluronic acid in reducing airways inflammation in patients with cystic fibrosis - preliminary results","volume":"12 Suppl 1","author":"Brivio","year":"2013","journal-title":"Journal of Cystic Fibrosis"},{"issue":"6","key":"10.1002\/14651858.CD001506.pub5-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1089\/jamp.2015.1256","article-title":"Pilot Randomized Controlled Trial Evaluating the Effect of Hypertonic Saline With and Without Hyaluronic Acid in Reducing Inflammation in Cystic Fibrosis","volume":"29","author":"Brivio","year":"2016","journal-title":"Journal of Aerosol Medicine and Pulmonary Drug Delivery"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0091|cit91","first-page":"303","article-title":"Durability of hypertonic saline for enhancing mucociliary clearance in cystic fibrosis","volume":"45 Suppl 33","author":"Brown","year":"2010","journal-title":"Pediatric Pulmonology"},{"issue":"5","key":"10.1002\/14651858.CD001506.pub5-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.jcf.2018.01.001","article-title":"Hypertonic saline has a prolonged effect on mucociliary clearance in adults with cystic fibrosis","volume":"17","author":"Trimble","year":"2018","journal-title":"Journal of Cystic Fibrosis"},{"issue":"11","key":"10.1002\/14651858.CD001506.pub5-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1007\/s12325-010-0076-8","article-title":"Hyaluronic acid improves \"pleasantness\" and tolerability of nebulized hypertonic saline in a cohort of patients with cystic fibrosis","volume":"27","author":"Buonpensiero","year":"2010","journal-title":"Advances in Therapy"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1016\/S1569-1993(10)60246-9","article-title":"Hyaluronic acid improves tolerability of hypertonic saline in CF patients","volume":"9 Suppl 1","author":"Buonpensiero","year":"2010","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0095|cit95","first-page":"243","article-title":"Inhaled hyaluronic acid improves pleasantness and tolerability of nebulised hypertonic saline in patients with cystic fibrosis","volume":"44 Suppl 32","author":"Buonpensiero","year":"2009","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0096|cit96","unstructured":"Comparison of the tolerability of two formulations of hypertonic saline in cystic fibrosis patients clinicaltrials.gov\/ct2\/show\/NCT01658449"},{"issue":"9","key":"10.1002\/14651858.CD001506.pub5-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/ppul.23749","article-title":"Overnight delivery of hypertonic saline by nasal cannula aerosol for cystic fibrosis","volume":"52","author":"Corcoran","year":"2017","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0098|cit98","unstructured":"A study of lung clearance after hypertonic saline delivery using the tpad device clinicaltrials.gov\/show\/nct02141191"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD001506.pub5-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/S1569-1993(08)60090-9","article-title":"Hypertonic saline: effect on mucus rheology and spirometry","volume":"7","author":"De Cono","year":"2008","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0100|cit100","unstructured":"A randomised trial of the effect of timing of nebulised hypertonic saline in relation to airway clearance physiotherapy, in people with cystic fibrosis lung disease trialsearch.who.int\/Trial2.aspx?TrialID=ACTRN12611000673943"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0101|cit101","first-page":"eS308","article-title":"Hypertonic saline before vs during vs after physiotherapy techniques for airway clearance in people with cystic fibrosis: A randomised trial","volume":"97","author":"Dentice","year":"2011","journal-title":"Physiotherapy"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0102|cit102","first-page":"384","article-title":"A randomised trial of the effect of timing of hypertonic saline inhalation in relation to airway clearance physiotherapy in adults with cystic fibrosis","volume":"45 Suppl 33","author":"Dentice","year":"2010","journal-title":"Pediatric Pulmonology"},{"issue":"1","key":"10.1002\/14651858.CD001506.pub5-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S1836-9553(12)70070-X","article-title":"Adults with cystic fibrosis prefer hypertonic saline before or during airway clearance techniques: a randomised crossover trial","volume":"58","author":"Dentice","year":"2012","journal-title":"Journal of Physiotherapy"},{"issue":"1","key":"10.1002\/14651858.CD001506.pub5-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S1836-9553(12)70070-X","article-title":"Online Supplementary Material - Table 3: Individual outcome data to \"Adults with cystic fibrosis prefer hypertonic saline before or during airway clearance techniques: a randomised crossover trial\" [online]","volume":"58","author":"Dentice","year":"2012","journal-title":"Journal of Physiotherapy"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0105|cit105","first-page":"251","article-title":"Efficacy of amiloride and hypertonic saline in cystic fibrosis","volume":"Suppl 25","author":"Donaldson","year":"2003","journal-title":"Pediatric Pulmonology"},{"issue":"3","key":"10.1002\/14651858.CD001506.pub5-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa043891","article-title":"Mucus clearance and lung function in cystic fibrosis with hypertonic saline","volume":"354","author":"Donaldson","year":"2006","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD001506.pub5-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa043891","article-title":"Online supplement to 'Mucus clearance and lung function in cystic fibrosis with hypertonic saline'","volume":"354","author":"Donaldson","year":"2006","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0108|cit108","unstructured":"Efficacy of amiloride and hypertonic saline in cystic fibrosis clinicaltrials.gov\/ct2\/show\/NCT00274391"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0109|cit109","unstructured":"Pilot trial of the tolerability of hypertonic saline when delivered by a high-output nebuliser twice or four times daily to people with cystic fibrosis trialsearch.who.int\/Trial2.aspx?TrialID=ACTRN12606000053527"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0110|cit110","first-page":"292","article-title":"Tolerability of hypertonic saline when delivered rapidly via the Eflow\u00ae rapid nebulizer in subjects with cystic fibrosis","volume":"41 (Suppl 29)","author":"Elkins","year":"2006","journal-title":"Pediatric Pulmonlogy"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0111|cit111","unstructured":"The effect of inhalation with hypertonic saline (7%) on lung function and sputum rheology in cystic fibrosis patients www.clinicaltrialsregister.eu\/ctr-search\/search?query=2007-002707-40"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0112|cit112","unstructured":"Genkova N Bosheva M Ivancheva D Inhaled hypertonic saline solution in cystic fibrosis 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin 1998"},{"issue":"5","key":"10.1002\/14651858.CD001506.pub5-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jcf.2012.12.008","article-title":"A randomized controlled trial of inhaled L-arginine in patients with cystic fibrosis","volume":"12","author":"Grasemann","year":"2013","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0114|cit114","first-page":"293","article-title":"A randomized placebo controlled study on the effects of L-arginine inhalation in patients with cystic fibrosis\u00a0","volume":"46 Suppl 34","author":"Grasemann","year":"2011","journal-title":"Pediatric Pulmonology\u00a0"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/S1569-1993(11)60099-4","article-title":"Inhaled L-arginine in patients with cystic fibrosis - a randomized controlled trial","volume":"10 Suppl 1","author":"Grasemann","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0116|cit116","unstructured":"The short term safety and efficacy of inhaled L-arginine in patients with cystic fibrosis clinicaltrials.gov\/ct2\/show\/NCT00405665"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0117|cit117","unstructured":"Comparison of the nebulized mannitol with nebulized hypertonic saline on pulmonary function in patients with cystic fibrosis trialsearch.who.int\/Trial2.aspx?TrialID=IRCT20180307038994N1"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0118|cit118","unstructured":"Study the Effectiveness of Outpatient treatment in Cystic Fibrosis Patients in Exacerbation Phase trialsearch.who.int\/Trial2.aspx?TrialID=IRCT20191112045413N2"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0119|cit119","unstructured":"Evaluation of the effectiveness of 7% plus hypertonic saline in comparison with 7% hypertonic saline in reducing the growth of Pseudomonas aeruginosa in lung of the patient with cystic fibrosis disease trialsearch.who.int\/Trial2.aspx?TrialID=IRCT20201017049055N1"},{"issue":"1","key":"10.1002\/14651858.CD001506.pub5-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1164\/ajrccm.156.1.9512074","article-title":"Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease","volume":"156","author":"King","year":"1997","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"Suppl 31","key":"10.1002\/14651858.CD001506.pub5-BIB0121|cit121","first-page":"121S","article-title":"Study of the mucociliary and cough clearance in patients with mucoviscidosis and evaluation of hypertonic sodium chorlide solution influence on them","volume":"16","author":"Kobylyansky","year":"2000","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0122|cit122","unstructured":"Durability of hypertonic saline for enhancing mucociliary clearance in cystic fibrosis clinicaltrials.gov\/show\/NCT01094704"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0123|cit123","unstructured":"Effects of inhaled hypertonic saline in children with cystic fibrosis trialsearch.who.int\/Trial2.aspx?TrialID=ISRCTN13412080"},{"issue":"1","key":"10.1002\/14651858.CD001506.pub5-BIB0124|cit124","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13052-017-0376-6","article-title":"Effects of inhaled hypertonic (7%) saline on lung function test in preschool children with cystic fibrosis: results of a crossover, randomized clinical trial","volume":"43","author":"Nenna","year":"2017","journal-title":"Italian Journal of Pediatrics"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0125|cit125","unstructured":"Timing of hypertonic saline inhalation relative to airways clearance in cystic fibrosis clinicaltrials.gov\/ct2\/show\/NCT01753869"},{"issue":"1","key":"10.1002\/14651858.CD001506.pub5-BIB0126|cit126","doi-asserted-by":"publisher","first-page":"e000168","DOI":"10.1136\/bmjresp-2016-000168","article-title":"Timing of hypertonic saline and airway clearance techniques in adults with cystic fibrosis during pulmonary exacerbation: pilot data from a randomised crossover study","volume":"4","author":"O'Neill","year":"2017","journal-title":"BMJ Open Respiratory Research"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD001506.pub5-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"A134","DOI":"10.1136\/thoraxjnl-2016-209333.238","article-title":"Exploring the timing of hypertonic saline (HTS) and airways clearance techniques (ACT) in cystic fibrosis (CF): a cross over study","volume":"71","author":"O\u2019Neill","year":"2016","journal-title":"Thorax"},{"issue":"S35","key":"10.1002\/14651858.CD001506.pub5-BIB0128|cit128","first-page":"364","article-title":"Tolerability and acceptability in patients with cystic fibrosis (CF) of two formulations of 7% hypertonic saline: a prospective multicenter clinical study","volume":"47","author":"Ros","year":"2012","journal-title":"Pediatric Pulmonology"},{"issue":"2","key":"10.1002\/14651858.CD001506.pub5-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1089\/jamp.2012.1034","article-title":"Hyaluronic acid improves the tolerability of hypertonic saline in the chronic treatment of cystic fibrosis patients: a multicenter, randomized, controlled clinical trial","volume":"27","author":"Ros","year":"2014","journal-title":"Journal of Aerosol Medicine and Pulmonary Drug Delivery"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0130|cit130","unstructured":"Study of long-term treatment with hypertonic saline in patients with cystic fibrosis clinicaltrials.gov\/ct2\/show\/NCT01377792"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0131|cit131","first-page":"360","article-title":"Study of the efficacy of long-term treatment with high volume compared to standard volume of hypertonic saline on pulmonary exacerbations in patients with cystic fibrosis","volume":"47 (S35)","author":"Ruiz de Valbuena Maiz","year":"2012","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/S1569-1993(16)30178-3","article-title":"Short-term effects of hypertonic saline nebulization combined with oscillatory positive expiratory pressure in cystic fibrosis:randomised crossover trial","volume":"15 Suppl 1","author":"Herrero Cortina","year":"2016","journal-title":"Journal of Cystic fibrosis"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0133|cit133","unstructured":"Positive expiratory pressure during inhalation of hypertonic saline in patients with cystic fibrosis clinicaltrials.gov\/ct2\/show\/NCT02303808"},{"issue":"Suppl 60","key":"10.1002\/14651858.CD001506.pub5-BIB0134|cit134","first-page":"PA1369","article-title":"Hypertonic saline nebulization combined with oscillatory positive expiratory pressure accelerate sputum clearance in cystic fibrosis: A randomised crossover trial","volume":"48","author":"San Miguel Pagola","year":"2016","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.physio.2019.11.001","article-title":"Impact of hypertonic saline nebulisation combined with oscillatory positive expiratory pressure on sputum expectoration and related symptoms in cystic fibrosis: a randomised crossover trial","volume":"107","author":"San Miguel-Pagola","year":"2020","journal-title":"Physiotherapy"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0136|cit136","unstructured":"Saline hypertonic in preschoolers with cystic fibrosis and lung structure as measured by computed tomography (CT) apps.who.int\/trialsearch\/Trial3.aspx?trialid=ACTRN12615001067561"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0137|cit137","unstructured":"Saline hypertonic in preschoolers and lung structure as measured by computed tomography www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2015-004143-39-NL"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0138|cit138","unstructured":"Saline hypertonic in preschoolers with cystic fibrosis and lung structure as measured by computed tomography (CT) trialsearch.who.int\/Trial2.aspx?TrialID=NTR5502"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0139|cit139","unstructured":"Saline hypertonic in preschoolers + CT (SHIP-CT) clinicaltrials.gov\/ct2\/show\/NCT02950883"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0140|cit140","unstructured":"Saline hypertonic in preschoolers and lung structure as measured by computed tomography www.who.int\/trialsearch\/Trial2.aspx?TrialID=NTR5502 2015"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"S255","DOI":"10.1016\/S1569-1993(21)01962-7","article-title":"Effect of inhaled hypertonic saline on structural lung disease in preschool children with cystic fibrosis. The SHIP-CT study","volume":"20 Suppl 2","author":"Tiddens","year":"2021","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0142|cit142","unstructured":"Tiddens HA Chen Y Andrinopoulou ER Davis SD Rosenfeld M Ratjen F The effect of inhaled hypertonic saline on lung structure in children aged 3-6 years with cystic fibrosis (SHIP-CT): a multicentre, randomised, double-blind, controlled trial The Lancet. Respiratory Medicine S2213-2600 21 00546 4 10.1016\/S2213-2600(21)00546-4"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1016\/S1569-1993(21)01085-7","article-title":"The effect of hypertonic saline treatment in pre-schoolers with cystic fibrosis on lung structure as measured by chest computed tomography. SHIP-CT study","volume":"20 Suppl 1","author":"Tiddens","year":"2021","journal-title":"Journal of Cystic Fibrosis"},{"issue":"2","key":"10.1002\/14651858.CD001506.pub5-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1159\/000111818","article-title":"Chest physiotherapy in cystic fibrosis: short-term effects of autogenic drainage preceded by wet inhalation of saline versus autogenic drainage preceded by intrapulmonary percussive ventilation with saline","volume":"76","author":"Van Ginderdeuren","year":"2008","journal-title":"Respiration"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD001506.pub5-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/S1569-1993(11)60259-2","article-title":"Influence of inhaled hypertonic saline (NaCl 6%) before or during autogenic drainage on sputum weight, oxygen saturation, heart frequency and dyspnea in cystic fibrosis patients","volume":"10","author":"Van Ginderdeuren","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD001506.pub5-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/S1569-1993(08)60271-4","article-title":"Influence of inhaled hypertonic saline combined with airway clearance on SpO2, heart rate, dyspnoea and wet sputum weight in hospitalised CF patients","volume":"7","author":"Vanlaethem","year":"2008","journal-title":"Journal of Cystic Fibrosis"},{"issue":"Meeting Abstrac","key":"10.1002\/14651858.CD001506.pub5-BIB0147|cit147","first-page":"A3342","article-title":"Effect of early intervention with inhaled hypertonic saline on lung function in infants and toddlers with cystic fibrosis diagnosed by neonatal screening","volume":"191","author":"Balinotti","year":"2015","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/S1569-1993(15)30159-4","article-title":"Effect of early intervention with inhaled hypertonic saline on lung function in infants and toddlers with cystic fibrosis (CF) diagnosed by neonatal screening","volume":"14 Suppl 1","author":"Teper","year":"2015","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0149|cit149","unstructured":"Trial of different concentrations of nebulised saline for cystic fibrosis saline at lower tonicity in cystic fibrosis (SALTI-CF) trial apps.who.int\/trialsearch\/Trial3.aspx?trialid=ACTRN12610000754044"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/S1569-1993(13)60056-9","article-title":"Saline at a lower tonicity in cystic fibrosis (SALTI-CF) trial - a randomised controlled trial comparing 0.9% v 3% v 6% nebulised saline","volume":"12 Suppl 1","author":"Dwyer","year":"2013","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0151|cit151","unstructured":"Hofmann T Senier I Ziersch A Geidel C Regnis J Lindemann H Additive effects of amiloride and hypertonic saline on respiratory ion transport in cystic fibrosis [abstract] Proceedings of the 21st European Cystic Fibrosis Conference; 1997; Davos 1997 119"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0152|cit152","first-page":"281","article-title":"Pilot study of inhaled sodium bicarbonate: safety and ph changes after 1-2 doses","volume":"51 (Suppl 45)","author":"Lennox","year":"2016","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0153|cit153","unstructured":"Effects of inhaled bicarbonate on airway pH in cystic fibrosis clinicaltrials.gov\/show\/NCT03391414"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"S7, Abstract no","DOI":"10.1016\/S1569-1993(14)60023-0","article-title":"Inhaled 7% hypertonic saline treatment in preschool children with cystic fibrosis [abstract]","volume":"13 Suppl 2","author":"Palacio","year":"2014","journal-title":"Journal of Cystic Fibrosis"},{"issue":"8","key":"10.1002\/14651858.CD001506.pub5-BIB0155|cit155","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1513\/AnnalsATS.202010-1336SD","article-title":"Evaluating the impact of stopping chronic therapies after modulator drug therapy in cystic fibrosis: The SIMPLIFY Clinical Trial Study Design","volume":"18","author":"Mayer-Hamblett","year":"2021","journal-title":"Annals of the American Thorac Society"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0156|cit156","unstructured":"Mayer-Hamblett N Ratjen F Russell R Donaldson SH Riekert KA Sawicki GS Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials Lancet Respiratory Medicine S2213 2600(22)00434-9 10.1016\/S2213-2600(22)00434-9"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0157|cit157","unstructured":"Impact of Discontinuing Chronic Therapies in People With Cystic Fibrosis on Highly Effective CFTR Modulator Therapy (SIMPLIFY) clinicaltrials.gov\/ct2\/show\/NCT04378153"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0158|cit158","unstructured":"A randomised open-label trial to assess change in respiratory function for people with cystic fibrosis (pwCF) established on triple combination therapy (Kaftrio\u2122) after rationalisation of nebulised mucoactive therapies (the CF STORM trial) trialsearch.who.int\/Trial2.aspx?TrialID=ISRCTN14081521"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0159|cit159","unstructured":"Clearing lungs with ENAC inhibition in cystic fibrosis (CLEAN-CF) clinicaltrials.gov\/ct2\/show\/NCT02343445"},{"issue":"6","key":"10.1002\/14651858.CD001506.pub5-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/humu.10041","article-title":"Cystic fibrosis: a worldwide analysis of CFTR mutations - correlation with incidence data and application to screening","volume":"19","author":"Bobadilla","year":"2002","journal-title":"Human Mutation"},{"issue":"6","key":"10.1002\/14651858.CD001506.pub5-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/ppul.20619","article-title":"Predictors of mortality in adults with cystic fibrosis","volume":"42","author":"Courtney","year":"2007","journal-title":"Pediatric Pulmonolgy"},{"issue":"Suppl 12","key":"10.1002\/14651858.CD001506.pub5-BIB0162|cit162","first-page":"A201","article-title":"Combined effects of hypertonic saline and rhDNase on cystic fibrosis sputum in-vitro","volume":"20","author":"Dasgupta","year":"1995","journal-title":"Pediatric Pulmonology"},{"issue":"5","key":"10.1002\/14651858.CD001506.pub5-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1164\/ajrccm.154.5.8912731","article-title":"Cystic fibrosis","volume":"154","author":"Davis","year":"1996","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"1","key":"10.1002\/14651858.CD001506.pub5-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"10","key":"10.1002\/14651858.CD001506.pub5-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1056\/NEJM199409083311003","article-title":"Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis","volume":"331","author":"Fuchs","year":"1994","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD001506.pub5-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1136\/thx.2007.077784","article-title":"Multiple-breath inert gas washout and spirometry versus structural structural lung disease in cystic fibrosis","volume":"63","author":"Gustafsson","year":"2008","journal-title":"Thorax"},{"issue":"7414","key":"10.1002\/14651858.CD001506.pub5-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0168|cit168","unstructured":"Higgins JP Altman DG Sterne JA Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017 Available from training.cochrane.org\/handbook\/archive\/v5.2"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1126\/science.2570460","article-title":"Identification of the cystic fibrosis gene: Genetic analysis","volume":"245","author":"Kerem","year":"1989","journal-title":"Science"},{"issue":"5","key":"10.1002\/14651858.CD001506.pub5-BIB0170|cit170","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008649.pub4","article-title":"Inhaled mannitol for cystic fibrosis","author":"Nevitt","year":"2020","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD001506.pub5-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1378\/chest.08-1190","article-title":"Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection","volume":"135","author":"Quittner","year":"2009","journal-title":"Chest"},{"issue":"6","key":"10.1002\/14651858.CD001506.pub5-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/ppul.1950170613","article-title":"Consensus conference: practical applications of Pulmozyme. September 22, 1993","volume":"17","author":"Ramsey","year":"1993","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0173|cit173","unstructured":"Review Manager (RevMan) The Nordic Cochrane Centre, The Cochrane Collaboration 2014"},{"issue":"3","key":"10.1002\/14651858.CD001506.pub5-BIB0174|cit174","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001127.pub5","article-title":"Dornase alfa for cystic fibrosis","author":"Yang","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD001506.pub5-BIB0175|cit175","volume-title":"Respiratory pharmacology and therapeutics","author":"Ziment","year":"1978"},{"issue":"2","key":"10.1002\/14651858.CD001506.pub5-BIB0176|cit176","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001506","article-title":"Nebulised hypertonic saline for cystic fibrosis","author":"Wark","year":"1999","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD001506.pub5-BIB0177|cit177","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001506","article-title":"Nebulised hypertonic saline for cystic fibrosis","author":"Wark","year":"2000","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD001506.pub5-BIB0178|cit178","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001506.pub2","article-title":"Nebulised hypertonic saline for cystic fibrosis","author":"Wark","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD001506.pub5-BIB0179|cit179","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001506.pub3","article-title":"Nebulised hypertonic saline for cystic fibrosis","author":"McDonald","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD001506.pub5-BIB0180|cit180","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001506.pub4","article-title":"Nebulised hypertonic saline for cystic fibrosis","author":"Wark","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T06:48:58Z","timestamp":1705387738000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD001506.pub5"}},"subtitle":[],"editor":[{"name":"Cochrane Cystic Fibrosis and Genetic Disorders Group","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2023,6,14]]},"references-count":180,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd001506.pub5","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,14]]}}}